216 related articles for article (PubMed ID: 29555965)
21. Effect of decreasing the affinity of the class II-associated invariant chain peptide on the MHC class II peptide repertoire in the presence or absence of H-2M.
Honey K; Forbush K; Jensen PE; Rudensky AY
J Immunol; 2004 Apr; 172(7):4142-50. PubMed ID: 15034026
[TBL] [Abstract][Full Text] [Related]
22. Evidence for invariant chain 85-101 (CLIP) binding in the antigen binding site of MHC class II molecules.
Bangia N; Watts TH
Int Immunol; 1995 Oct; 7(10):1585-91. PubMed ID: 8562503
[TBL] [Abstract][Full Text] [Related]
23. DM influences the abundance of major histocompatibility complex class II alleles with low affinity for class II-associated invariant chain peptides via multiple mechanisms.
Rinderknecht CH; Roh S; Pashine A; Belmares MP; Patil NS; Lu N; Truong P; Hou T; Macaubas C; Yoon T; Wang N; Busch R; Mellins ED
Immunology; 2010 Sep; 131(1):18-32. PubMed ID: 20408893
[TBL] [Abstract][Full Text] [Related]
24. Complexes of two cohorts of CLIP peptides and HLA-DQ2 of the autoimmune DR3-DQ2 haplotype are poor substrates for HLA-DM.
Fallang LE; Roh S; Holm A; Bergseng E; Yoon T; Fleckenstein B; Bandyopadhyay A; Mellins ED; Sollid LM
J Immunol; 2008 Oct; 181(8):5451-5461. PubMed ID: 18832702
[TBL] [Abstract][Full Text] [Related]
25. HLA-DP, HLA-DQ, and HLA-DR have different requirements for invariant chain and HLA-DM.
van Lith M; McEwen-Smith RM; Benham AM
J Biol Chem; 2010 Dec; 285(52):40800-8. PubMed ID: 20959457
[TBL] [Abstract][Full Text] [Related]
26. Modulation of antigen presentation and class II expression by a class II-associated invariant chain peptide.
Zechel MA; Chaturvedi P; Lee-Chan EC; Rider BJ; Singh B
J Immunol; 1996 Jun; 156(11):4232-9. PubMed ID: 8666792
[TBL] [Abstract][Full Text] [Related]
27. Quality control of MHC class II associated peptides by HLA-DM/H2-M.
Vogt AB; Arndt SO; Hämmerling GJ; Kropshofer H
Semin Immunol; 1999 Dec; 11(6):391-403. PubMed ID: 10625593
[TBL] [Abstract][Full Text] [Related]
28. A novel family of human leukocyte antigen class II receptors may have its origin in archaic human species.
Temme S; Zacharias M; Neumann J; Wohlfromm S; König A; Temme N; Springer S; Trowsdale J; Koch N
J Biol Chem; 2014 Jan; 289(2):639-53. PubMed ID: 24214983
[TBL] [Abstract][Full Text] [Related]
29. HLA-DR4 molecules in neuroendocrine epithelial cells associate to a heterogeneous repertoire of cytoplasmic and surface self peptides.
Muntasell A; Carrascal M; Serradell L; Veelen Pv Pv; Verreck F; Koning F; Raposo G; Abián J; Jaraquemada D
J Immunol; 2002 Nov; 169(9):5052-60. PubMed ID: 12391221
[TBL] [Abstract][Full Text] [Related]
30. Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs.
van Ham SM; Grüneberg U; Malcherek G; Bröker I; Melms A; Trowsdale J
J Exp Med; 1996 Nov; 184(5):2019-24. PubMed ID: 8920889
[TBL] [Abstract][Full Text] [Related]
31. Introducing endogenous antigens into the major histocompatibility complex (MHC) class II presentation pathway. Both Ii mediated inhibition and enhancement of endogenous peptide/MHC class II presentation require the same Ii domains.
Frauwirth K; Shastri N
Immunology; 2001 Apr; 102(4):405-15. PubMed ID: 11328374
[TBL] [Abstract][Full Text] [Related]
32. Type 1 diabetes associated HLA-DQ2 and DQ8 molecules are relatively resistant to HLA-DM mediated release of invariant chain-derived CLIP peptides.
Zhou Z; Reyes-Vargas E; Escobar H; Rudd B; Rockwood AL; Delgado JC; He X; Jensen PE
Eur J Immunol; 2016 Apr; 46(4):834-45. PubMed ID: 26707565
[TBL] [Abstract][Full Text] [Related]
33. An altered invariant chain protein with an antigenic peptide in place of CLIP forms SDS-stable complexes with class II alphabeta dimers and facilitates highly efficient peptide loading.
Barton GM; Rudensky AY
Int Immunol; 1998 Aug; 10(8):1159-65. PubMed ID: 9723702
[TBL] [Abstract][Full Text] [Related]
34. HLA-DM and the MHC class II antigen presentation pathway.
Jensen PE; Weber DA; Thayer WP; Chen X; Dao CT
Immunol Res; 1999; 20(3):195-205. PubMed ID: 10741860
[TBL] [Abstract][Full Text] [Related]
35. Class II-associated invariant chain peptide-independent binding of invariant chain to class II MHC molecules.
Thayer WP; Ignatowicz L; Weber DA; Jensen PE
J Immunol; 1999 Feb; 162(3):1502-9. PubMed ID: 9973407
[TBL] [Abstract][Full Text] [Related]
36. Regulation of the class II MHC pathway in primary human monocytes by granulocyte-macrophage colony-stimulating factor.
Hornell TM; Beresford GW; Bushey A; Boss JM; Mellins ED
J Immunol; 2003 Sep; 171(5):2374-83. PubMed ID: 12928384
[TBL] [Abstract][Full Text] [Related]
37. Quantitative defect in staphylococcal enterotoxin A binding and presentation by HLA-DM-deficient T2.Ak cells corrected by transfection of HLA-DM genes.
Albert LJ; Denzin LK; Ghumman B; Bangia N; Cresswell P; Watts TH
Cell Immunol; 1998 Jan; 183(1):42-51. PubMed ID: 9578718
[TBL] [Abstract][Full Text] [Related]
38. Tetraspan microdomains distinct from lipid rafts enrich select peptide-MHC class II complexes.
Kropshofer H; Spindeldreher S; Röhn TA; Platania N; Grygar C; Daniel N; Wölpl A; Langen H; Horejsi V; Vogt AB
Nat Immunol; 2002 Jan; 3(1):61-8. PubMed ID: 11743588
[TBL] [Abstract][Full Text] [Related]
39. Human duodenal epithelial cells constitutively express molecular components of antigen presentation but not costimulatory molecules.
Byrne B; Madrigal-Estebas L; McEvoy A; Carton J; Doherty DG; Whelan A; Feighery C; O'Donoghue DP; O'Farrelly C
Hum Immunol; 2002 Nov; 63(11):977-86. PubMed ID: 12392850
[TBL] [Abstract][Full Text] [Related]
40. Promiscuous binding of invariant chain-derived CLIP peptide to distinct HLA-I molecules revealed in leukemic cells.
van Luijn MM; van de Loosdrecht AA; Lampen MH; van Veelen PA; Zevenbergen A; Kester MG; de Ru AH; Ossenkoppele GJ; van Hall T; van Ham SM
PLoS One; 2012; 7(4):e34649. PubMed ID: 22563374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
